研究目的
To summarize the evolution of LITT especially for brain gliomas and a possible outlook of the future.
研究成果
LITT is currently used as a treatment for some focal recurrent glioma lesions on a personalized basis. The concepts of superior efficacy of immunotherapy through disruption of the BBB has been proposed, but still lacks proof. A significant benefit of LITT for gliomas might well rely on advances in immunotherapy and other systemic therapies that benefit from BBB disruption.
研究不足
The paper does not provide specific experimental limitations but mentions the lack of prospective randomized or case-control trials demonstrating a statistically significant effect of LITT in gliomas.
